Quercetin

Quercetin

SCHEMBL4815328

O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12.[NaH]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.97
KMT2A Q03164 9/20 0.97
CYP1A2 P05177 8/20 0.97
CYP1A1 P04798 7/20 0.97
CYP1B1 Q16678 7/20 0.97
KDM4E B2RXH2 6/20 0.97
HSD17B10 Q99714 6/20 0.97
CYP3A4 P08684 6/20 0.97
MAPT P10636 6/20 0.97
POLH Q9Y253 6/20 0.97
ABCB1 P08183 6/20 0.97
CYP2C9 P11712 5/20 0.97
RECQL P46063 5/20 0.97
IPMK Q8NFU5 5/20 0.97
IP6K2 Q9UHH9 5/20 0.97
XDH P47989 5/20 0.97
FTO Q9C0B1 5/20 0.97
ALOX15 P16050 4/20 0.97
HIF1A Q16665 4/20 0.97
POLB P06746 4/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetin SCHEMBL31507620 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL118425 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29723041 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL19723 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL17629824 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29351036 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29353785 0.99 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL3786991 0.97 MEN1 (0.97) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL6756842 0.97 MEN1 (0.97) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL22103 0.97 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110407895-B Method for extracting and separating quercetin from polygonum cuspidatum leaves 重庆市中药研究院 2022-11-29 CN claimed
EP-2665467-A2 FLAVONOL COMPOSITIONS Ono, Mitsunori (US) 2013-11-27 EP claimed
WO-2012099930-A2 FLAVONOL COMPOSITIONS ONO MITSUNORI (US) 2012-07-26 WO claimed
US-20120183587-A1 FLAVONOL COMPOSITIONS LINES, THOMAS CHRISTIAN (CH) 2012-07-19 US claimed
US-7399475-B1 Inactivated microorganisms comprising substances having pharmacological activity TONER ENTERPRISE INC. (LI) 2008-07-15 US claimed
EP-1171103-B1 INACTIVATED MICROORGANISMS COMPRISING SUBSTANCES HAVING PHARMACOLOGICAL ACTIVITY TONER ENTPR INC (LI) 2004-12-29 EP claimed
US-4755504-A Pharmaceutical composition from Tienchi LIU YAGUANG (US) 1988-07-05 US claimed
WO-2025038371-A1 SALT-LOADED SOLID LIPID NANOPARTICLES LOADED WITH AN ACTIVE AGENT PURDUE RESEARCH FOUNDATION (US) 2025-02-20 WO disclosed
CN-110407895-B Method for extracting and separating quercetin from polygonum cuspidatum leaves 重庆市中药研究院 2022-11-29 CN disclosed
US-7399475-B1 Inactivated microorganisms comprising substances having pharmacological activity TONER ENTERPRISE INC. (LI) 2008-07-15 US disclosed
US-20060062822-A1 Medical devices to treat or inhibit restenosis MEDTRONIC VASCULAR, INC. (US) 2006-03-23 US disclosed
EP-1171103-B1 INACTIVATED MICROORGANISMS COMPRISING SUBSTANCES HAVING PHARMACOLOGICAL ACTIVITY TONER ENTPR INC (LI) 2004-12-29 EP disclosed
EP-1171103-A2 INACTIVATED MICROORGANISMS COMPRISING SUBSTANCES HAVING PHARMACOLOGICAL ACTIVITY Toner Enterprise Inc. (LI) 2002-01-16 EP disclosed
WO-2000064417-A2 INACTIVATED MICROORGANISMS COMPRISING SUBSTANCES HAVING PHARMACOLOGICAL ACTIVITY TONER ENTERPRISE INC. (LI) 2000-11-02 WO disclosed
WO-1996016667-A1 COSMETIC COMPOSITIONS COMPRISING PILOCARPUS JABORANDI, ALOE VERA EXTRACTS PVP SOCIEDADE ANÔNIMA (BR) 1996-06-06 WO disclosed
US-4755504-A Pharmaceutical composition from Tienchi LIU YAGUANG (US) 1988-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060062822-A1 Medical devices to treat or inhibit restenosis ALDOA, AKR1B1, AKR1C2 MEN1 2391/4885KMT2A 3025/4885CYP1A2 870/4885
US-20120183587-A1 FLAVONOL COMPOSITIONS CYP2F1, F3, TEAD3 MEN1 2383/4885KMT2A 2991/4885CYP1A2 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.